Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis
58
Citation
20
Reference
10
Related Paper
Citation Trend
Abstract:
Aim: To compare the efficacy and tolerability of olsalazine sodium with enteric‐coated mesalazine in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis. Patients and methods: Patients with mild to moderate active ulcerative colitis were randomized to receive either olsalazine sodium, 3 g/day ( n = 88), or mesalazine, 3 g/day ( n = 80), for up to 12 weeks. Results: Of the patients treated with olsalazine sodium, 52.2% achieved endoscopic remission, compared with 48.8% of patients treated with mesalazine. This difference was not significant ( P = 0.67). There was a non‐significant trend for patients with left‐sided colitis or a more severe endoscopic grade to achieve remission if they were treated with olsalazine sodium than if they were treated with mesalazine. Both treatments were comparable with respect to clinical activity index and an investigator’s global assessment. Seventy patients reported one or more adverse events; adverse events were seen in 45% of olsalazine sodium‐treated patients and in 36% of mesalazine‐treated patients. Eleven patients treated with olsalazine sodium and nine patients treated with mesalazine withdrew from the study because of adverse events. One patient treated with olsalazine sodium compared with two treated with mesalazine stopped treatment because of diarrhoea. Serious adverse events occurred in three patients treated with olsalazine sodium and in four treated with mesalazine. Conclusion: Therapeutic effectiveness and tolerance to the treatment did not differ between olsalazine sodium, 3 g/day, and mesalazine, 3 g/day, in inducing endoscopic remission in patients with mild to moderate active ulcerative colitis within 12 weeks of treatment.Keywords:
Mesalazine
Tolerability
Objective: To improve the clinical understanding of ulcerative colitis,we analyze the clinical data of 1 cases of ulcerative colitis and the literature was reviewed. Methods: The patient was treated by mesalazine tablet,saccharomyces boulardii sachet and kangfuxin solution for retention- enema. Results: The patients were cured through systematic treatment. Conlusions: Mesalazine tablet,saccharomyces boulardii sachet and kangfuxin solution can effectively improve relative symptom in treating ulcerative colitis.
Mesalazine
Saccharomyces boulardii
Enema
Cite
Citations (0)
Objective To observe the clinical effects of probiotics drug in the treatment of mild and moderate ulcerative colitis.Methods Total 129 patients with mild to moderate active ulcerative colitis were divided into treatment group (65 patients) and control group (64 patients) at first stage.the former were treated with probiotics drug, the later were treated with mesalazine. the study lasted for 12 weeks and patients were assessed by clinical remission rate and the time to clinical remission.At second stage 91 patients in remission of ulcerative colitis were radomized into two groups to receive probiotics drug (43 patients in treatment group ) or mesalazine (48 patients in control group).After 12 months relapse-free time and relapse rate were determined.Results At first stage,after 12 weeks treatment there were no statistical differences(P0.05)between treatment group and control group in clinical remission rate and the time to clinical remission.At second stage, there were no differences between two groups(P0.05)in relapse-free time and relapse rate.Conclusion Probiotics drug are effective in treatment of mild and moderate active ulcerative colitis and preventing relapse.
Mesalazine
Sulfasalazine
Drug treatment
Cite
Citations (1)
0bjective: To evaluate the effect of mesalazine combined with ligustrazine in treating ulcerative colitis patients. Methods: Sixty patients with ulcerative colitis were randomly divided into observation group and control group, thirty patients in each group. On the foundation treatment of ulcerative colitis, the control group received mesalazine 1.0 g, three times a day. And at the same time the observation group received Ligustrazine glucose 100 ml one time each day by injection. All the patients received a course of 8 weeks. Then the effect of the treatment was evaluated. Results: The total effective rate and significant efficiency rate of observation group were 90% and 70%, compared with control group's 80% and 50%, the diference was statistically significant (P0.05). Conclusion: The combination therapy in treatment of ulcerative colitis is better. It can improve the patient's clinical symptoms and signs better.
Mesalazine
Clinical efficacy
Cite
Citations (0)
Язвенный колит – аутоиммунное заболевание толстой кишки, проявляющееся развитием неспецифического воспаления его слизистой оболочки с обязательным поражением прямой кишки. Наиболее часто в клинической практике встречается левосторонний язвенный колит, легкая или среднетяжелая атака. Оптимальным способом лечения таких пациентов являются месалазины, однако применение препарата с рН-зависимой оболочкой может быть ограничено в связи с большим разнообразием значений рН у пациентов с воспалительными заболеваниями кишечника. Препаратами выбора в таких ситуациях являются покрытые этилцеллюлозой микрогранулы месалазина с пролонгированным высвобождением, позволяющие достигнуть максимального терапевтического эффекта. Для улучшения результатов терапии месалазинами необходимо комбинированное применение местного и системного препарата. При неэффективности данного подхода в качестве альтернативы системным глюкокортикостероидам можно рассмотреть вопрос о назначении будесонида ММХ с новой мультиматриксной системой высвобождения месалазина (multimatrix system, ММХ). Ulcerative colitis is an autoimmune disease of the colon, manifested by the development of non-specific inflammation of its mucous membrane with a mandatory lesion of the rectum. The most common in clinical practice is left-sided ulcerative colitis, a mild or moderate attack. The optimal treatment for such patients is mesalazine, but the use of the drug with a pH-dependent shell may be limited due to the large variety of pH values in patients with inflammatory bowel diseases. The drugs of choice in such situations are ethylcellulose-coated mesalazine microgranules with prolonged release, which allow to achieve the maximum therapeutic effect. To improve the results of mesalazine therapy, the combined use of a local and systemic drug is necessary. If this approach is ineffective, the use of budesonide MMH may be considered as an alternative to systemic glucocorticosteroids. Keywords: mesalazine, treatment scheme, therapy, ulcerative colitis, proctitis, left-side colitis, budesonide, suppositoria, delivery system, MMX.
Mesalazine
Cite
Citations (0)
Objective: To evaluate the efficacy of probiotics as maintenance treatment in ulcerative colitis.Methods: A total of 58 ulcerative colitis patients with remission were randomized to receive probiotics plus mesalazine(29 patients) and mesalazine(29 patients).Disease activity index and endoscopic and histological scores were calculated in both groups in 0,6,and 12 months and relapse was recorded.Results: No significant difference in relapse rate in 6(P=0.666) and 12 months(P=0.345) was noted between the 2 groups and the same result was found in disease activity index and endoscopic and histological scores in 0,6,and 12 months(P0.05).Conclusions: Mesalazin plus probiotics as maintenance treatment in ulcerative colitis has the same effect as mesalazine alone on maintaining remission of ulcerative colitis in the 1st year.It is unnecessary to use probiotics and mesalazine together as maintenance treatment in ulcerative colitis.
Mesalazine
Maintenance therapy
Cite
Citations (0)
Objective:To investigate ulcerative colitis(UC) in clinical characteristics,to treat effective ulcerative colitis.Methods:52 patients with ulcerative colitis patients were treated with the drug system specifications and enema fluid.Results:52 patients with ulcerative colitis condition was under control,obtained satisfactory clinical outcome.Conclusion:The sustained-release tablets plus mesalazine combined with enema for ulcerative colitis can reduce and prevent complications,to achieve the purpose of healing.
Mesalazine
Enema
Sulfasalazine
Cite
Citations (0)
Fish oil (FO) and mesalazine have well-known anti-inflammatory and antioxidant effects; on the other hand, information related to combined intrarectal administration of FO and mesalazine is limited. The present study was conducted to make comparison on therapeutic effectiveness of rectally administered FO and mesalazine in rats with trinitrobenzenesulfonic acid (TNBS)-induced colitis. Wistar rats were randomly assigned to 5 groups as (1) Control, (2) Colitis, (3) Colitis + Mesalazine (Colitis + M), (4) Colitis + Fish Oil (Colitis + F), and (5) Colitis + Mesalazine + Fish Oil (Colitis + M + F). Intrarectally administered TNBS induced colitis. At the end of the trial, the rats' macroscopic and histopathologic lesions were rated and tumour necrosis factor (TNF)-α, Interleukin 6 (IL6), glutathione reductase (GR), glutathione peroxidase (GP), myeloperoxidase (MPO), malondialdehyde (MDA), Superoxide dismutase (SOD), Total nitrate and nitrite, and catalase (CAT) in serum and tissue were detected. As a result of macroscopic and microscopic examination, although separate administrations of FO and mesalazine partly decreased the damage, their combined administration decreased the damage scores significantly (p < 0.01). It was observed that separate and combined administrations of FO and mesalazine decreased the increase in the serum and tissue TNF-α and IL-6 levels caused by colitis (p < 0.05). It was observed that the serum MPO, serum GR, tissue SOD, tissue nitrite/nitrate values of both Colitis + M and Colitis + F groups were close to the control in terms of all the parameter values in Colitis + M + F group (p > 0.05). Also based on the histological results, the inflammation damage in the tissue caused by colitis in the Colitis + M + F group recovered significantly. We found that microscopic and macroscopic damage, serum IL-6 level decreased and increased serum and tissue GP and tissue GR values in Colitis + M + F group compared to Colitis + M and Colitis + F groups. Combined intrarectal administration of FO and mesalazine may bring a new insight concerning the treatment of ulcerative colitis.
Mesalazine
Cite
Citations (14)
Objective To evaluate the therapeutic effects of mesalazine, osalazine and sulfasalazine for patientswith ulcerative colitis. Methods 120 patients with ulcerative colitis were randomly divided into mesalazinegroup(n=40), osalazine group(n=39) and sulfasalazine group(n=41). The efficacy and adverse events of the three groups were observed after the treatment of 12 weeks. Results The rate of complete remission and overall effective rate of three groupswere30.0%, 28.2% and 51.2%; 75.0%, 76.9% and 92.7%, respectively. And the differences between mesalazine/osalazine and sulfasalazine were statistically significant(P 0.05). Conclusion Compared with mesalazine and osalazine, sulfasalazine is more effective in treatment of ulcerative colitis, but with a relatively higher incidence of adverse reactions.
Sulfasalazine
Mesalazine
Cite
Citations (0)
Objective To observe the efficacy of mesalamine in treatment of patients with ulcerative colitis. Methods One hundred and forty-four patients in our hospital were randomly divided into observation group and control group with 72 cases in each. The control group was treated with basic treatment and the observation group was given mesalamine on this basis,adverse reactions and the efficacy of the two groups were observed. Results The efficacy of the observation were obviously better than those of the control group and the difference were statistically significant(P0.05). The adverse reactions of the two groups were not statistically significant(P0.05). Conclusion Mesalamine has good curative effect on ulcerative colitis,it was safe and reliable.
Mesalazine
Clinical efficacy
Cite
Citations (0)
Mesalazine
Sulfasalazine
Aminosalicylic acid
Cite
Citations (1)